Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Martin A. Maier(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Alnylam Pharmaceuticals (United States)), Shigeo Matsuda(Alnylam Pharmaceuticals (United States)), Ju Liu(Alnylam Pharmaceuticals (United States)), Scott Barros(Alnylam Pharmaceuticals (United States)), William Querbes(Alnylam Pharmaceuticals (United States)), Ying K. Tam(Encana (Canada)), Steven M. Ansell(Encana (Canada)), Varun Kumar(Alnylam Pharmaceuticals (United States)), June Qin(Alnylam Pharmaceuticals (United States)), Xuemei Zhang(Alnylam Pharmaceuticals (United States)), Qianfan Wang(Alnylam Pharmaceuticals (United States)), Sue Panesar(Alnylam Pharmaceuticals (United States)), Renta Hutabarat(Alnylam Pharmaceuticals (United States)), Mary Carioto(Alnylam Pharmaceuticals (United States)), Julia Hettinger(Alnylam Pharmaceuticals (United States)), Kandasamy Pachamuthu(Alnylam Pharmaceuticals (United States)), David Butler(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Bo Pang(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Alnylam Pharmaceuticals (United States)), Barbara L. Mui(Encana (Canada)), Xinyao Du(Encana (Canada)), Pieter R. Cullis(University of British Columbia), Thomas D. Madden(Encana (Canada)), Michael J. Hope(Encana (Canada)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States))
Molecular Therapy
June 25, 2013
Cited by 615Open Access
Full Text

Abstract

In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid nanoparticles (LNPs), and the novel ionizable lipids that comprise them, will be important materials in this emerging field of medicine. A persistent theme in the use of materials for biomedical applications has been the incorporation of biodegradability as a means to improve biocompatibility and/or to facilitate elimination. Therefore, the aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality. As a representative example of this novel class of biodegradable lipids, the lipid evaluated in this work displays rapid elimination from plasma and tissues, substantially improved tolerability in preclinical studies, while maintaining in vivo potency on par with that of the most advanced lipids currently available. In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid nanoparticles (LNPs), and the novel ionizable lipids that comprise them, will be important materials in this emerging field of medicine. A persistent theme in the use of materials for biomedical applications has been the incorporation of biodegradability as a means to improve biocompatibility and/or to facilitate elimination. Therefore, the aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality. As a representative example of this novel class of biodegradable lipids, the lipid evaluated in this work displays rapid elimination from plasma and tissues, substantially improved tolerability in preclinical studies, while maintaining in vivo potency on par with that of the most advanced lipids currently available.


Related Papers